Breaking News, Collaborations & Alliances

Samsung BioLogics and UCB Sign Third Drug Manufacturing Deal

The CDMO will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Samsung BioLogics and UCB have agreed to an additional drug substance manufacturing deal under which Samsung will also produce UCB’s anti-tau candidate to treat progressive supranuclear palsy, pending regulatory approvals. UCB’s anti-tau candidate is currently in Phase I clinical studies.   UCB is a biopharmaceutical company, headquartered in Belgium, with over 90 years of innovation focusing on neurology and immunology, with an annual revenue of €4.6 billion in 2018.   “Our ai...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters